Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Opdivo plus Cabometyx reduced the risk of death by 40%.
MK-6482 shrank tumors in 24% of people with advanced renal cell carcinoma.
FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.
Ed Doelp lives with his wife, Dawn, in Smithville, New Jersey. Now in his 60s, he was diagnosed with kidney cancer in 2012.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
Sidharth Ghosh is an IT professional, sportsman and kidney cancer survivor in Delhi, India.
Two years later, Michael Mullan’s cancer is still at bay because of immunotherapy and targeted chemotherapy.
Dual checkpoint inhibitors improve response rate and survival for people with intermediate or poor risk.
Immunotherapy combo was more effective and better tolerated for first-time treatment.
Are immunotherapy and targeted therapies ready to replace toxic chemotherapy?
The FDA previously approved Cabometyx in 2016 for treatment of patients with advanced RCC who have received prior anti-angiogenic therapy.
FDA approves sunitinib malate (Sutent) for the adjuvant treatment of adults at risk for kidney cancer recurrence.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.